Indeed, only one study has assessed the impact of gonadotropin type used for COH protocol in women with PCOS [64], showing a significantly lower estradiol peak (E2), fewer intermediate-sized follicles, lower number of oocytes retrieved and MII oocytes in hMG-group in comparison with recombinant FSH-group. Here, BRD2 is linked to polycystic ovary syndrome.